Veracyte’s Decipher Prostate Genomic Classifier is the only gene expression test included in the 2025 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for prostate cancer. This inclusion solidifies Decipher Prostate’s position as a leading diagnostic tool for assessing the risk of metastatic prostate cancer, enabling clinicians to personalize treatment strategies. The test’s inclusion in the guidelines is a significant validation of its clinical utility and performance.
For Veracyte, this news signifies market leadership and reinforces the strength of their diagnostic platform. For the broader medical community, it provides clinicians with a validated tool for enhanced risk stratification and treatment decision-making, potentially improving patient outcomes. Inclusion in the NCCN Guidelines often leads to broader insurance coverage and increased adoption by healthcare providers, signifying wider access for patients. This, in turn, provides an impetus for further research and development in the field.
The Decipher Prostate test analyzes a 22-gene signature derived from whole-transcriptome analysis using RNA and machine learning. This technology allows for a precise assessment of the risk of metastasis. The test’s clinical utility has been demonstrated in numerous peer-reviewed studies encompassing a large patient population. This rigorous validation process, coupled with its unique inclusion in the NCCN Guidelines, positions Decipher Prostate as a highly reliable and valuable tool in prostate cancer management.
This inclusion in the NCCN guidelines marks a significant advancement in prostate cancer diagnostics and personalized medicine. It is expected to solidify Decipher Prostate’s position as a standard-of-care diagnostic tool, leading to greater accessibility for patients and potentially improved treatment outcomes. Furthermore, it validates Veracyte’s research-driven approach and strengthens its position as a leader in cancer diagnostics, paving the way for future innovations in the field. The broader impact on prostate cancer management is likely to be significant, influencing treatment paradigms and emphasizing the importance of genomic testing in guiding patient care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
